SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations
Qure.ai is scaling-up the integration of its AI-powered chest x-ray interpretation tool that can benefit early and easy detection of lung diseases including lung cancer.
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
APAC region contributed around 50% of the in-vitro diagnostics market in 2022
Positive opinions based on significant survival benefit
The only definitive way to diagnose and stage lung cancers is through biopsies
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
Subscribe To Our Newsletter & Stay Updated
